Lunai Bioworks Inc. (LNAI) · Oct 22, 2026 · Delisting

Lunai Bioworks delisting set as CFO exits, no OTC plan

Nasdaq delisting — $9.0M stockholders’ deficit versus $2.5M minimum equity

Lunai Bioworks is voluntarily leaving Nasdaq after a $9.0M equity deficit, while its CFO and a director resign and no OTC quotation is planned.

Lunai Bioworks is a preclinical biotechnology and AI-healthcare company trying to advance biodefense, neurology and diagnostic platforms while operating under severe funding pressure; its latest annual filing indicated less than one month of cash under its current plan.

The listing failure is now becoming an access and financing problem, not just a compliance issue. Nasdaq cited a $9,024,946 stockholders’ deficit against a $2,500,000 equity requirement, and the company will not seek a hearing. 〔0〕 By choosing voluntary withdrawal and declining to arrange an over-the-counter quotation, Lunai is accepting that its common stock may have no meaningful trading market after Nasdaq suspension.

The filing removes the company’s near-term path back to a public-market listing. Trading is expected to be suspended on October 30, 2026, with Form 25 planned around November 2 and delisting expected around November 12. 〔1〕 The direction was partly known because the company was already under a mandatory Nasdaq hearings-panel monitor and had disclosed serious financial strain, but the decision not to contest delisting and not to support OTC quotation makes the consequence more definitive.

Management and oversight capacity are deteriorating at the same time. CFO Nathen Fuentes resigned immediately, no successor or interim principal financial officer has been appointed, and director Douglas Calder’s departure leaves the audit committee and compensation committee below Nasdaq’s minimum membership requirements. 〔2〕 The resignations were stated not to reflect disagreements, but the practical issue is that accounting, reporting and board oversight now depend on temporary arrangements while the company is already trying to preserve liquidity.

SEC reporting may continue briefly, but the company is preparing to reduce its disclosure obligations. Lunai says its September 30, 2026 quarterly report remains due unless reporting obligations are formally suspended, after which it intends to file Form 15 if eligible. 〔3〕 That creates a limited reporting transition rather than a clean operational reset.

Bottom line: This filing turns Lunai’s financing and Nasdaq-compliance weakness into a planned exit from the public market, while losing its CFO and a director further complicates execution. It materially weakens the company’s ability to fund and transparently advance its biotech programs, even though the underlying distress was already visible.

What to watch next

Form 25 filing, expected November 2

Original filing on SEC EDGAR

More Lunai Bioworks Inc. news

Lunai Bioworks delisting set as CFO exits, no OTC plan | LNAI Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.